Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02671461 · ClinicalTrials.gov registry record · Phase 2

Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"

A Phase 2 study of Thrombosis, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 2
Development phase
16
Enrollment target
20
Study locations

NCT02671461 is a Phase 2 study of Thrombosis that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 16 participants, below the 470-participant average among 28 other Thrombosis trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02671461, a Phase 2 study of Thrombosis, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 2
Development phase
16 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to determine whether BMS-986141 is effective in reducing the recurrence of stroke in people who recently had a stroke, or a transient ischemic attack (known as a TIA or "mini stroke") and are receiving acetylsalicylic acid (also known as aspirin or ASA) to treat the stroke or TIA.

Conditions Studied

Thrombosis

Interventions

  • OTHER Placebo
  • DRUG Aspirin
  • DRUG BMS-986141

Study Locations (20)

Florida

  • University Of Florida - Gainesville
  • University Of Florida Hsc/Jacksonville - Jacksonville
  • Florida Hospital - Orlando
  • Intercoastal Medical Group - Sarasota

North Carolina

  • Local Institution - Chapel Hill
  • Duke University Medical Center - Durham
  • Guilford Medical Associates, Pa - Greensboro

Massachusetts

  • Tufts Medical Center - Boston
  • Boston Medical Center - Boston

Arizona

  • Banner University Medical Ctr - Phoenix

California

  • Hoag Memorial Hospital - Newport Beach

Delaware

  • Local Institution - Newark

Illinois

  • Presence Saint Joseph Medical Center - Joliet

Kentucky

  • University Of Louisville - Louisville

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2016-04-25
Est. Completion 2017-03-31
Phase Phase 2

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02671461

The ClinicalTrials.gov registry entry for NCT02671461 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 470-participant average among 28 other Thrombosis trials with a reported enrollment target (97% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Thrombosis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT02671461 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, North Carolina, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02671461 about?

NCT02671461 is a clinical study titled "Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"". The purpose of this study is to determine whether BMS-986141 is effective in reducing the recurrence of stroke in people who recently had a stroke, or a transient ischemic attack (known as a TIA or "mini stroke") and are receiving acetylsalicylic acid (also known as aspirin or ASA) to treat the stro...

What is the current status of trial NCT02671461?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2016-04-25. Estimated completion is 2017-03-31.

What conditions does trial NCT02671461 study?

This clinical trial studies the following conditions: Thrombosis.

What interventions are being tested in trial NCT02671461?

The interventions under investigation include: Placebo (OTHER), Aspirin (DRUG), BMS-986141 (DRUG).

Who is sponsoring clinical trial NCT02671461?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02671461 being conducted?

This trial has 20 study locations across Arizona, California, Delaware, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Thrombosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Thrombosis

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.